FDA Approves Vevye (cyclosporine) Ophthalmic Solution for the Treatment of the Signs and Symptoms of Dry Eye Disease
Novaliq GmbH announced that the U.S. Food and Drug Administration (FDA) has approved Vevye™
(cyclosporine ophthalmic solution) 0.1% for the treatment of the signs and symptoms of dry eye disease. Vevye (development name CyclASol®) is the first and only cyclosporine solution indicated for the treatment of signs and symptoms of dry eye disease with efficacy demonstrated after 4 weeks of treatment.
Dosage is for one drop of VEVYE twice a day in each eye approximately 12 hours apart. The water-free product does not contain antimicrobial preservatives.
Dry eye disease (DED) affects millions of Americans and is one of the most common ocular surface disorders. A leading cause of DED is inflammation of the ocular surface. The chronic inflammatory nature causes progressive corneal surface damage that can lead to direct or indirect visual impairment.
